The COVID-19 Cure: Hydroxychloroquine, Chloroquine, Remdesivir, Lopinavir, Favilavir and Blood plasma Treatment

There is no direct-acting  antiviral treatment recommended for COVID-19. Therefore, it requires supportive care for people with the virus to relieve symptoms. Isolation and treatment should be performed in a hospital with adequate conditions for isolation and protection

Critical cases must be admitted to the intensive care unit /ICU immediately, which require mechanical ventilation and supportive treatment to avoid deaths as much as possible

Antivirals Treatment

At present, no specific antivirals have been proven to inhibit the replication SARS-COV-2. Worldwilde doctors are testing various antiviral drugs in patients with coronavirus

Lopinavir/ ritonavir

Lopinavir is an antiretroviral protease inhibitor utilized in combination with ritonavir to ensure adequate lopinavir exposure for the treatment of (HIV) infection, has in vitro activity against the SARS-CoV and shows up to have some activity against MERS-CoV in experimental animals. In any case, there was no difference in time to clinical improvement

Favilavir

Favilavir is an antiviral drug that is mainly taken as an effective treatment for influenza in Japan and it showed encouraging profile for blocking the novel coronavirus in early clinical trials by inhibiting the RNA-dependent RNA polymerase for fighting RNA infections

Remdesivir

Remdesivir is an antiviral drug that was developed to treat Ebola and was found effective against SARS-COV-2 where it inhibits viral replication through the premature termination of RNA transcription and has in-vitro activity against SARS-CoV-2

Remdesivir doesn’t target the virus itself, it targets the system the virus uses to replicate itself and cannot infect other cells by making the wrong code because remdesivir has tricked the enzyme into believing it is adenosine, so thus the virus cannot reproduce in your body when it tries to use the polymerase enzyme again to copy the viral genetic code, it will make the wrong genetic code

Hydroxychloroquine/ Chloroquine Treatment

Hydroxychloroquine and chloroquine are oral drugs that have been used for treatment of malaria and certain inflammatory conditions, and being studied in treating viral infection where being used to inhibit SARS-CoV-2 in vitro and potentially treat coronavirus (COVID-19)

• Chloroquine is Anti-malarial drug and is effective in treating coronavirus patients, experts have confirmed the drug is safe to use and may offer the same benefit for patients in serious condition

• Hydroxychloroquine  treat rheumatoid arthritis, systemic lupus erythematosus and porphyria cutanea tarda, meanwhile hydroxychloroquine have more potent antiviral activity against SARS-CoV-2

The combination of Hydroxychloroquine and the antibiotic azithromycin is successful treatment right now and it achieves satisfactory results, but at the same time could be harmful as well by prolonging the QTC interval potentially leading to arrhythmias

How does it work?

Hydroxychloroquine / chloroquine acts by inhibiting SARS-COV-2 from cell invasion by changing the configuration of the ACE2 receptor in the cell and the peak protein in the coronavirus where it prevents release of viral RNA into the cell, So hydroxychloroquine can slow infections from coronavirus by blocking the ACE2 receptors on your cells

Antibodies Teatment / Blood plasma Treatment

Special immune plasma products have been used to determine an effective treatment for the illness, so how is plasma helping fight against COVID-19?

Convalescent plasma obtained from patients who recovered from novel coronavirus  has been suggested as a potential therapy that can provide passive immunity to specific antibodies against SARS-CoV2

This serum can be used as a vaccine for severaly and critically ill COVID-19 paients, or as a treatment measure. This treatment method may be successful with many patients after recovery from the disease, that convalescent plasma therapy was associated with a reduction in mortality

The clinical criteria for quarantine release and discharge

•  The patient's condition is stable, clear consciousness
•  The patient's temperature is normal for more than 3 days at 37°
•  Stable patient breathing
•  Significant improvement in Lung imaging with no sign of organ dysfunction
•  The patient with no symptoms and tow negative PCR tests taken 24 hours apart
•  The patients should minimize family and social contact and to wear a face  mask